Changing patterns and survival improvements of young breast cancer in China and SEER database, 1999-

来源 :中国癌症研究(英文版) | 被引量 : 0次 | 上传用户:yifeng9131120
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
Objective:Breast cancer in young females was usually considered more aggressive and requires aggressive therapy.We investigated whether early detection and improved treatments changed the patts of characteristics,management and outcomes of young breast cancer patients over time.Methods:Females under 40 years of age diagnosed with breast cancer during the periods 1999-2017 and 1999-2015 were identified in the Fudan University Shanghai Cancer Center (FUSCC) and the population-based Surveillance,Epidemiology,and End Results (SEER) registry,respectively.Clinicopathologic characteristics and treatment information were collected.Patients diagnosed before 2013 were followed up.Results:The proportions of young breast cancer patients were 15.0% and 5.3% in the FUSCC and SEER cohorts,respectively.In the FUSCC cohort,there was a significant increase in the proportion of ductal carcinoma in situ (DCIS) (from 8.8% to 16.9%;P<0.0001) and it remained stable in SEER cohort.The proportion of T1-stage tumors increased dramatically in the FUSCC cohort (from 35.3% to 41.9%;P=0.008),whereas it decreased in SEER cohort (from 42.4% to 33.0%;P<0.0001).The percentage of estrogen receptor (ER)-positive cancers was consistently increased in both the invasive ductal carcinoma (IDC) and DCIS patients in the two cohorts.Breastconserving surgery and immediate implant reconstruction after masteetomy both exhibited increased use over time in the FUSCC cohort.Both the FUSCC and SEER cohorts showed a significantly better prognosis in the recent time period.Conclusions:With the increased early-stage and ER-positive diseases in young patients as well as better systemic tteatment strategies,improved survival has been observed in recent years.There has been a substantial deescalation in surgical therapies in young breast cancer patients.
其他文献
As the first monoclonal antibody against vascular endothelial growth factor (VEGF),bevacizumab (BEV) is a definitely controversial antiangiogenic therapy in bre
磁性纳米材料在目前的医学领域中应用广泛,在肿瘤热疗、药物载体、核磁影像中都有所应用.本文就磁流体修饰及其在肿瘤治疗中的应用做一综述.
Objective:China have implemented population-based esophageal cancer (EC) screening programs,however,the participant rates were relatively low.This study was con
原发性肝细胞癌(简称肝癌)目前尚无有效的治疗手段,五年生存率很低.由于癌肿本身代谢异常或癌组织对机体发生各种影响引起的内分泌或代谢方面的症候群称副癌综合征,在临床诊
Objective:Growing evidence indicates that FAT atypical cadherin 1 (FAT1) has aberrant genetic alterations and exhibits potential tumor suppressive function in e
Objective:To investigate the clinical significance of MET gene amplification in patients with gastric cancer in the palliative setting.Methods:MET amplification
Aim: To investigate the androgen receptor (AR) isoform expressions in human prostatic cancer tissue and LNCaP cell line. Methods: With high resolution isoelectr
随着肿瘤综合治疗方案的广泛应用,胸部肿瘤治疗的疗效有了显著的提高,但是放射性肺损伤( radiation-induced lung injury)的出现,使得其成为限制胸部肿瘤放射治疗靶区剂量提
Objective:To develop and validate a radiomics-based predictive risk score (RPRS) for preoperative prediction of lymph node (LN) metastasis in patients with rese